Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dual-target CAR-T cells BGT007

A preparation of human T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for two as of yet undisclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon administration, the dual-target CAR-T cells BGT007 specifically recognize and induce selective toxicity in tumor cells expressing the two TAAs.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	bispecific CAR T cells BGT007 dual-target CAR T cells BGT007
Code name:	BGT 007 BGT-007 BGT007

dual-target CAR-T cells BGT007

Search NCI's Drug Dictionary